Oakland, CA 1/23/17—Clinical genomics data analysis and reporting provider Omicia has purchased Spiral Genetics for an undisclosed amount. Spiral Genetics offers tools for NGS variant detection, including its graph-based, population-specific reference genome and lossless data-compression technologies. “The strategic integration of Spiral’s technologies effectively cements Omicia’s leadership position in precision medicine,” commented Omicia CEO Matt Tindall. “By removing the need to access multiple software platforms, Omicia improves quality, accuracy and turnaround time, removing major bottlenecks for clinical adoption.”

Omicia’s Opal Clinical variant interpretation and clinical reporting platform is designed for NGS clinical research and diagnostic testing. This acquisition adds variant detection capabilities to the platform. Mr. Tindall told IBO, “Before the acquisition, Omicia did tertiary genomic variant interpretation and reporting only.” He said, “The Spiral acquisition makes it possible to provide these tools as part of Omicia’s complete end-to-end solution. Spiral’s tools also offer a unique expansion of capabilities beyond the Broad Best Practices pipeline, including highly accurate structural variation detection and population-scale comparison.” Omicia’s Opal solution works with targeted sequencing panels, exomes and whole genomes, and in silico gene panels.